Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-India celebrates 1 billion COVID-19 vaccine doses with song and dance

Thu, 21st Oct 2021 06:21

* India reaches milestone after slow start in mid-January

* Huge disparity between partly and fully vaccinated people

* WHO, UNICEF congratulate India, urge it to resume COVAX
supplies
(Adds graphics, UNICEF comment)

By Krishna N. Das

NEW DELHI, Oct 21 (Reuters) - India celebrated the milestone
of administering 1 billion COVID-19 vaccine doses on Thursday,
with the government promoting the achievement in song and video
even as a recent drop in inoculations worries healthcare
providers.

After a slow beginning in the middle of January, India's
immunisation campaign has covered three-quarters of its 944
million adults with at least one dose but only 31% with two. The
government wants all adults to get vaccinated this year.

"India scripts history," Prime Minister Narendra Modi said
on Twitter. "We are witnessing the triumph of Indian science,
enterprise and collective spirit of (1.3 billion) Indians."

Modi marked the occasion by interacting with healthcare
workers and a security guard at a government hospital in New
Delhi. The health ministry announced musical and other
programmes across the country, and special illuminations of
national monuments including a colonial-era jail.

Nearly 90% of the vaccines administered in India have come
from the Serum Institute of India (SII), which produces a
licensed version of the AstraZeneca drug. SII has more
than tripled its capacity since April and can now produce 220
million vaccine doses a month.

SII has also slowly resumed exports for the first time since
April, when the government stopped all overseas sales to meet
domestic demand as infections rose dramatically.

The World Health Organization (WHO), which relies heavily on
India for supplies to its global vaccine-sharing platform COVAX,
congratulated the country for reaching the landmark.

"India's progress must be viewed in the context of the
country's commendable commitment and efforts to ensure that
these life-saving vaccines are accessible globally," said Poonam
Khetrapal Singh, regional director WHO South-East Asia.

COVAX partner UNICEF also congratulated India and said it
looked forward to "hearing details about the expected timeline
and volumes of supplies to be made" to the global facility.

Reuters has reported that India has delayed supplies of the
AstraZeneca vaccine to COVAX https://www.reuters.com/world/india/india-delays-covid-19-vaccine-supplies-who-backed-covax-sources-say-2021-10-19.
New Delhi has been annoyed by the WHO's repeated delay in
adding India's own Covaxin shot to the world body's
emergency-use listing https://twitter.com/DrTedros/status/1450574012027920402,
something both parties discussed this week as well as exports.

India has so far reported 34.1 million COVID-19 cases and
more than 452,000 deaths, most during a second wave of
infections of the Delta variant between April and May.

A "sizeable number https://www.reuters.com/article/health-coronavirus-india/many-indians-skipping-second-covid-shot-despite-record-vaccine-stocks-idUSL4N2RF2G3
" of people in India have not taken their second dose by the due
date despite adequate supplies, the health ministry said on
Tuesday, as new infections fell to their lowest since early
March.

Daily shots have averaged 5 million this month, a fifth of
September's peak, though states are sitting on record stocks of
more than 100 million as domestic output of the AstraZeneca
vaccine soars.

Despite the current low number of infections, ministry
officials have been urging people to get vaccinated fast,
especially as the ongoing festival season means family
gatherings and mass shopping, raising the risk of a new wave of
infections.

(Reporting by Krishna N. Das; Editing by Lincoln Feast and
Giles Elgood)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.